相关实验视频

Updated: Jul 18, 2025

An Ex Vivo Choroid Sprouting Assay of Ocular Microvascular Angiogenesis

An Ex Vivo Choroid Sprouting Assay of Ocular Microvascular Angiogenesis

Published on: August 6, 2020

用口服小分子抑制剂向FSCN1,用于治疗眼部新血管化

Wen Bai^1,2, Jun-Song Ren^1,2, Min Xia^1,2

¹The Affiliated Eye Hospital, Nanjing Medical University, Nanjing, China.

Journal of translational medicine

|August 18, 2023

概括

阻断法斯同源1 (FSCN1) 在治疗眼部新血管化方面显示出有前途. 一种口服抑制剂,NP-G2-044,有效降低了新血管化,并增强了抗VEGF疗法.

科学领域:

眼科医生眼科眼科
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

眼部新血管化是视力丧失的主要原因之一.
目前的抗VEGF治疗有局限性,包括耐药性和副作用.
需要新的治疗点来对抗致盲眼病.

研究的目的:

调查法辛同类1 (FSCN1) 在眼睛新血管化中的作用.
评估口服FSCN1抑制剂NP-G2-044作为潜在治疗方法的疗效和安全性.

主要方法:

生物信息学和RT-PCR用于评估OIR和CNV模型中的FSCN1表达.
在体外和体内测试 (Transwell,伤口愈合,管道形成,发芽) 来研究FSCN1和NP-G2-044.
对NP-G2-044.的药理动力学和安全性评估.
使用共免疫沉,qRT-PCR和西方斑点的机制研究.

主要成果:

FSCN1对血管生成至关重要,在OIR和CNV模型中高度表达.
口服NP-G2-044抑制了内皮细胞的迁移,发芽,和filopodia形成.
当与抗VEGF治疗相结合时,NP-G2-044安全地减少了OIR和CNV的发展,并改善了结果.

结论:

FSCN1抑制是眼部新血管化的潜在治疗策略.
NP-G2-044证明了疗效和安全性,提供了一个新的治疗途径.
使用NP-G2-044和抗VEGF药物的联合治疗可以克服耐药性并改善治疗结果.

关键词:

血管新生的产生.在FSCN1中.在NP-G2-044中使用.眼睛的病理眼睛的病理血管尖端细胞是血管尖端细胞

更多相关视频

In Vivo Multimodal Imaging and Analysis of Mouse Laser-Induced Choroidal Neovascularization Model

In Vivo Multimodal Imaging and Analysis of Mouse Laser-Induced Choroidal Neovascularization Model

Published on: January 21, 2018

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Published on: March 30, 2020

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...